S. Karagiannis (King’s College, UK) investigated in her presentation “Mechanisms of action for MOv18 IgE targeting folate receptor alpha-expressing tumours” whether antibodies engineered with Fc regions of IgE class may provide an alternative approach for treating solid tumours. Here, FOLR1 is linked to neoplasm.